Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Revenue (2023 - 2025)

Iovance Biotherapeutics has reported Revenue over the past 4 years, most recently at $86.8 million for Q4 2025.

  • Quarterly results put Revenue at $86.8 million for Q4 2025, up 17.74% from a year ago — trailing twelve months through Dec 2025 was $263.5 million (up 60.6% YoY), and the annual figure for FY2025 was $263.5 million, up 60.6%.
  • Revenue for Q4 2025 was $86.8 million at Iovance Biotherapeutics, up from $67.5 million in the prior quarter.
  • Over the last five years, Revenue for IOVA hit a ceiling of $86.8 million in Q4 2025 and a floor of $238000.0 in Q2 2023.
  • Median Revenue over the past 3 years was $49.3 million (2025), compared with a mean of $39.0 million.
  • Biggest five-year swings in Revenue: skyrocketed 15189.21% in 2024 and later rose 15.2% in 2025.
  • Iovance Biotherapeutics' Revenue stood at $482000.0 in 2023, then skyrocketed by 15189.21% to $73.7 million in 2024, then rose by 17.74% to $86.8 million in 2025.
  • The last three reported values for Revenue were $86.8 million (Q4 2025), $67.5 million (Q3 2025), and $60.0 million (Q2 2025) per Business Quant data.